

Clinical Trial Protocol

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

Study Title: Bougie use in Emergency Airway Management (BEAM)

Investigators: Brian Driver, MD; Lauren Klein, MD; Jon Cole, MD; Matt Prekker, MD, Johanna Moore, MD; Robert Reardon, MD; James Miner, MD

Phase: IV

Contact: Hennepin County Medical Center
Department of Emergency Medicine
701 Park Ave, Mailstop R2
Minneapolis, MN 55415
612.293.8286

Institutional Review Board Minneapolis Medical Research Foundation
701 Park Ave, Suite PP7.700
Minneapolis, MN 55415
612.873.5300

	Date
Protocol version 1.0:	15 December 2015
Protocol version 1.1:	18 May 2016

33
34
35

37 **Table of Contents**

38

39	Table of Contents.....	2
40	LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS	4
41	1 INTRODUCTION	5
42	1.1 Previous published literature	5
43	1.2 Rationale for further investigation	7
44	1.3 Known risks of the interventions	7
45	1.3.1 Known risks of orotracheal intubation without a bougie.....	8
46	1.3.2 Known risks of orotracheal intubation with a bougie.....	8
47	1.4 Proposed Study Population.....	8
48	2 STUDY OBJECTIVES.....	8
49	2.1 Primary outcome	8
50	2.2 Secondary outcomes	9
51	3 MEASUREMENT OF STUDY OUTCOMES.....	10
52	3.1 Measurement of primary outcome	10
53	3.2 Measurement of secondary outcomes.....	10
54	4 INVESTIGATIONAL PLAN	11
55	4.1 Overall Study Design and Plan.....	11
56	4.1.1 Study Population and Randomization.....	11
57	4.1.2 Study Treatment and Blinding.....	11
58	4.2 Assessments.....	11
59	4.2.1 Outcome Assessments.....	11
60	4.2.2 Safety Assessments	11
61	4.3 Study Duration.....	12
62	5 STUDY POPULATION SELECTION.....	13
63	5.1 Study Population.....	13
64	5.2 Inclusion Criteria	13
65	5.3 Exclusion Criteria	13
66	5.4 Subject Withdrawal Criteria	13
67	6 STUDY CONSENT	14
68	6.1 Research involves no more than minimal risk to the subjects	14
69	6.2 The waiver or alteration will not adversely affect the rights and welfare of	
70	the subjects	15
71	6.3 The research could not practicably be carried out without the waiver or	
72	alteration.....	15
73	6.3.1 Patient objection.....	16
74	6.3.2 LAR or Family member objection	16
75	6.4 Notification after enrollment.....	16
76	7 STUDY PROCEDURES	17
77	7.1 Study Entrance Criteria.....	17
78	7.2 Enrollment.....	17
79	7.3 Baseline and ED Data Collection	17
80	7.4 Adverse Event Assessments	17

81	7.4.1	Adverse Event Monitoring and Period of Observation	18
82	7.4.2	Reporting Serious Adverse Events	18
83	7.5	Safety-Related Stopping Rules	18
84	8	PLANNED STATISTICAL METHODS	19
85	8.1	General Considerations	19
86	8.2	Sample size calculation	19
87	8.3	Method of Assigning Study Patients to Treatment Groups	19
88	8.4	Population Description	19
89	8.4.1	Analysis Populations	20
90	8.4.2	Treatment Compliance	20
91	8.5	Outcome Analysis	20
92	8.6	Statistical/Analytic Issues	20
93	8.6.1	Handling of Missing Data	20
94	8.6.2	Interim Analysis and Data Monitoring	21
95	9	ADMINISTRATIVE CONSIDERATIONS	22
96	9.1	Institutional Review Board Approval	22
97	9.2	Data monitoring committee	22
98	9.3	Protocol Violations/Deviations	22
99	9.4	Premature Closure of the Study	22
100	10	LIST OF REFERENCES	23

101

102 **LIST OF ABBREVIATIONS AND DEFINITIONS OF**
103 **TERMS**

104

Abbreviation	Definition
AE	Adverse event
DSMB	Data safety and monitoring board
ED	Emergency Department
ETT	Endotracheal tube
GEB	Gum-elastic bougie
HCMC	Hennepin County Medical Center
IRB	Institutional review board
ITT	Intention-to-treat
LAR	Legally-authorized representative
SAE	Serious Adverse Event

105

1 INTRODUCTION

Rapid and definitive airway management is an essential skill for all emergency physicians. Orotracheal intubation is the most common means to obtain a definitive airway, and is classically performed using an endotracheal tube with an intubating stylet inserted into the tube for rigidity. The tube and stylet are passed under direct vision. Using these methods, the majority of patients in the emergency department can be successfully intubated, and therefore successfully oxygenated and ventilated.

The concept of first-pass success, that is, passing the endotracheal tube successfully on the first intubation attempt, is paramount in emergency airway management. It has been shown that for every attempt after the first, complications increase dramatically.¹ While emergency medicine has been improving airway management and first pass success over the past several years, a large cross-sectional sample demonstrated that first pass success remains approximately 85%.² First pass success is likely lower in the hands of less experienced operators, such as emergency medicine residents in training. Therefore, there is substantial room for improvement. A simple adjunct to endotracheal intubation, the gum elastic bougie (GEB), may increase first pass success and decrease rates of intubation-associated hypoxemia.

The GEB is a 60 or 70-centimeter stylet with an approximately 30-degree angle at its tip. When used during an intubation attempt, the GEB is passed between the vocal cords; then the endotracheal tube is passed over the GEB into the trachea. The GEB essentially serves as a flexible guide into the trachea.

It can enable successful intubation in difficult airways due to its flexible material, allowing the intubating provider to be able to direct its tip anteriorly through the vocal cords. Proper placement of the GEB can be performed by direct visualization, video assisted visualization, and also both the feeling of “clicks” as the GEB passes over tracheal rings and a “hard stop” when the GEB comes into contact with a mainstem bronchus at the level of the carina.^{3,4}

1.1 Previous published literature

The first report of adjunctive GEB use in difficult endotracheal intubation was in 1949, described by Macintosh.⁵ Although it did not receive much attention in the literature for many years thereafter, the late 1980’s and early 1990’s saw multiple case reports and case series describing the effectiveness of the GEB in these clinical scenarios.^{3,6-8} As the GEB became more popular, several larger series were published supporting its use. One series of 2000 anesthesiology incident reports of difficult intubations concluded that the most successful airway adjunct was the

150 GEB.⁹ Another retrospective trial found a 99% success rate when using the GEB
151 during 301 difficult intubations over an 8-year period.¹⁰

152
153 Several prospective studies have also been published describing the use of the GEB
154 in difficult airways. One prospective trial found that 199 out of 200 attempts at
155 placing the GEB in the trachea were successful.¹¹ In this study, the providers elected
156 to use the GEB due to a poor laryngeal view or failed attempts at conventional stylet
157 intubation. Another prospective observational cross-over study described the use of
158 the GEB in cadaveric airways.¹² The cadavers were manipulated to have either a
159 Cormack-Lehane Grade 1 or Grade 3 view, and emergency medicine residents
160 intubated them with either a stylet or a GEB. The authors found a trend toward
161 increased success in the GEB group in the Grade 3 view cadavers but this result did
162 not achieve statistical significance.

163
164 The first randomized study to assess the efficacy of the GEB was conducted in
165 1993.¹³ This study simulated cervical spine injuries to create a difficult airway. The
166 patients in this study had manual in-line stabilization maintained during intubation,
167 which significantly decreased the view of the larynx. Patients were randomized to
168 direct visualization versus intubation using a GEB. The authors found that all
169 patients who had failed intubation in the direct visualization group were
170 successfully intubated within 45 seconds using the GEB. Another randomized trial
171 describing GEB use was published in 1996.¹⁴ The authors of this study randomized
172 patients to a GEB versus a standard stylet during direct laryngoscopy. The authors
173 created difficult intubation scenario by simulating a Cormack-Lehane Grade 3 view
174 with laryngoscope placement. Each group had two attempts at intubation with their
175 randomized equipment before they could cross over. They found that the GEB group
176 was successful 96% of the time while the stylet group was successful 66% of the
177 time after the first two attempts, demonstrating compelling evidence for the use of
178 the GEB in difficult airways.

179
180 Certain types of difficult airways may be more amenable to GEB-facilitated
181 intubation. One scenario that has been well described is the difficult trauma airway,
182 particularly those with facial and neck trauma.^{13,15,16} The trauma airway provides a
183 unique set of complications to airway control including active hemorrhage,
184 distorted anatomy, and cervical immobility due to cervical collar use. Another
185 scenario in which the use GEB is commonly described is in the setting of pre-
186 hospital difficult airways.¹⁷⁻²⁰ Based on its observed success, one group reported
187 that the GEB became part of a pre-hospital institutional algorithm for difficult
188 airway management.¹⁷

189
190 Most of the evidence describing the use of the GEB has stemmed from the
191 anesthesiology literature, with relatively little reference to its use in the emergency
192 departments. Few studies describe emergency providers utilizing the GEB on airway
193 task-trainers,²¹ manikins,^{22,23} and cadavers,¹² but all are limited by artificial airway
194 simulations.

195

196 There are two observational trials in humans published in 2011 by the same group
197 of authors.^{24,25} These trials report data on the use of the GEB as a rescue device after
198 failed intubation. The success rates described in these trials were 20 out of 26
199 (76.9%) and 70 out of 88 (79.6%) attempts, respectively. These success rates are
200 lower than what is typically cited, but the authors identified limitations including the
201 fact that the participants in their study were residents using the GEB for the first
202 time, suggesting the need for education on its use prior to utilization in the
203 emergency department.

204
205

206 **1.2 Rationale for further investigation**

207

208 Based on this review of the literature, there is evidence supporting GEB use as an
209 adjunct for difficult airways. However, because it is not always possible to
210 anticipate a difficult airway, or even semi-difficult airway, before an intubation
211 attempt begins, the bougie may improve the overall success of routine intubations
212 as well, especially for patients with any difficult airway characteristics.

213

214 However, while the GEB has significant face validity in its ability to improve
215 intubation success, a large multi-center study demonstrated that only 3.5% of first
216 attempts use the GEB.² This speaks to the possibility that increasing the use of the
217 GEB, a simple, low-cost intervention, may improve first pass success and decrease
218 intubation-associated complications.

219

220 The practice in the Emergency Department at Hennepin County Medical Center
221 (HCMC), however, varies from nationwide practice in that the GEB is available for
222 every first intubation attempt. Based on the treating physicians preference, the GEB
223 may or may not be used on the first attempt. Thus, it is standard of care at HCMC to
224 use *and* not use the GEB on the first attempt. We have experienced faculty members,
225 many of whom are airway experts, who feel strongly on both sides, with some
226 stating that it should be used uniformly, and others saying that it should be reserved
227 for intubations that are not successful on the first attempt. Thus, there is a clinical
228 equipoise on whether to use or not use a GEB on the first attempt.

229

230 To our knowledge there are no randomized control trials studying first pass success
231 and peri-intubation hypoxemia with and without the use of a GEB. This proposed
232 research study will attempt to answer the question of whether the use of the GEB is
233 superior to non-use of the GEB in emergency department airway management.

234

235

236 **1.3 Known risks of the interventions**

237

238 While the procedure of endotracheal intubation has many inherent risks, there are
239 no significant differences in risk between orotracheal intubation with and without a
240 bougie.

241

242 **1.3.1 Known risks of orotracheal intubation without a bougie**

243

244 Risks of orotracheal intubation without a bougie include: inability to pass the ETT
245 and stylet past the hypopharynx through the vocal cords, and inability to slide the
246 endotracheal tube over the stylet. There are rare case reports of breakage of the
247 metal tip of the stylet. Patients intubated with an endotracheal tube without a
248 bougie are at risk for airway perforation, oropharyngeal trauma, laryngeal trauma,
249 tracheobronchial trauma, and esophageal intubation.

250

251

252 **1.3.2 Known risks of orotracheal intubation with a bougie**

253

254 Risks of orotracheal intubation with a bougie includes: inability to pass the GEB past
255 the hypopharynx through the vocal cords, and inability to pass the endotracheal
256 tube over the bougie ²⁵. There are rare mechanical complications that have been
257 reported with the GEB, including breakage of the GEB tip,²⁶ and fracture of the
258 material.²⁷ Major medical complications of GEB use are rare.. The reported
259 complications of GEB use include hemopneumothorax ²⁸, pharyngeal wall
260 perforation,²⁹ traumatic bleeding within the airway,^{30,31} and tracheal injury.³²
261 Several of these case reports describe patients with post-surgical and complex
262 airway anatomy, and GEB use as the sole inciting mechanism for the trauma is
263 debatable..

264

265

266

267

268 **1.4 Proposed Study Population**

269

270 Adult patients undergoing orotracheal intubation in the ED with a Macintosh blade
271 (using either video or direct laryngoscopy) for any indication will be randomized to
272 use of the GEB during the first intubation attempt. All other care will be at the
273 discretion of the treating emergency physician.

274

275

276

277

278 **2 STUDY OBJECTIVES**

279

280 **2.1 Primary outcome**

281

282 The primary outcome of this study will be first pass success.

283

284 First pass success is defined as placement of the endotracheal tube (ETT) into the
285 trachea on the first attempt. An attempt begins when the laryngoscope enters the
286 mouth, and ends if either of the following occur:
287 1. the laryngoscope leaves the mouth, regardless of whether an attempt was
288 made to pass the endotracheal tube or bougie.
289 2. if the operator cannot intubate the trachea with the first tube device (ETT or
290 bougie), and switches to any other tube device, even if the laryngoscope
291 blade remains in the mouth.

292
293

294 A patient will be considered to achieve the primary outcome if they are intubated
295 successfully on the first attempt.

296

297 Tracheal position of the ETT is confirmed immediately using a standard protocol
298 involving multiple modalities (physical exam, capnography, and chest x-ray, among
299 others).

300

301

302 **2.2 Secondary outcomes**

303

304 1) First pass success without hypoxemia. Hypoxemia is defined as a pulse
305 oximetry value (SpO₂) less than 90% at any point during intubation, or a
306 drop of more than 10% from baseline if starting below 90%. The outcome of
307 hypoxemia will be recorded beginning when the first attempt begins and
308 ending one minute after inflation of the ETT cuff.

309

310 A patient will be considered to achieve this outcome if 1) they are intubated
311 successfully on the first attempt, *and* 2) do not experience hypoxemia on the
312 first attempt.

313

314

315 2) Time to intubation (first attempt only). Time to intubation will be defined as
316 the time elapsed between the beginning of the intubation attempt to inflation
317 of the ETT cuff when the tube is in the trachea.

318

319 3) Esophageal intubation: defined as passage of the ETT into the esophagus,
320 with subsequent ventilation, and then removal. Clinically, esophageal
321 intubation is identified by the absence of end-tidal carbon dioxide, abnormal
322 physical exam, and hypoxia. This does not count passage of the ETT into the
323 esophagus during the attempt if the ETT is removed during the attempt.

324

325 4) Hypoxemia, as defined above.

326 **3 MEASUREMENT OF STUDY OUTCOMES**

327

328 **3.1 Measurement of primary outcome**

329

330 A trained research assistant will be present in the room for all study subjects. This
331 trained assistant will observe the intubation and record the number of attempts.
332 The intubating physician will also be asked the number of attempts at the end of the
333 case. In cases where there is a discrepancy between the research assistant and the
334 intubating physician, the video for the stabilization case will be reviewed to
335 determine the actual number of attempts.

336

337

338 **3.2 Measurement of secondary outcomes**

339

340 For secondary outcome 1): First pass success will be measured as described above.
341 For hypoxemia, a research assistant will record the SpO₂ at the beginning of the
342 attempt and every 20 seconds thereafter, until 1 minute after inflation of the ETT
343 cuff. The lowest SpO₂ will also be recorded, even if this does not fall at a 20-second
344 interval.

345

346 For secondary outcome 2): The research assistant will have a stopwatch and record
347 the time to intubation, as defined in 2.2.

348

349 For secondary outcome 3): The intubating physician will fill out a data collection
350 sheet after the intubation. This form will include whether there was an esophageal
351 intubation, as defined in 2.2.

352

353 For secondary outcome 4):. Hypoxemia will be measured, as described above in
354 secondary outcome 1).

355

356

357

358 **4 INVESTIGATIONAL PLAN**

359

360 **4.1 Overall Study Design and Plan**

361

362 This Phase IV study is designed as a randomized, unblinded, two-arm study that will
363 be conducted at a single center. The primary aim is to determine if first pass success
364 differs by more than 9% (absolute difference) in patients who use a GEB during the
365 first intubation attempt compared to those that do not.

366

367 **4.1.1 Study Population and Randomization**

368

369 Adult patients undergoing orotracheal intubation in the ED with a Macintosh blade
370 (using either video or direct laryngoscopy) for any indication will be enrolled into
371 the study.

372

373 If the patient meets all of the eligibility criteria, he/she will be enrolled and
374 randomized at a 1:1 ratio to undergo intubation with or without a GEB for the first
375 attempt. The randomization will be permuted-block with random block sizes of 2, 4,
376 6, 8, and 10. The randomization will be stratified into two groups: 1) those with any
377 of the following: cervical collar, obesity (gestalt), and apparent facial or neck
378 trauma; and 2) those with none of those characteristics. A trained research
379 coordinator who will not be performing any data collection or chart review during
380 the study will generate the treatment assignments.

381

382 The study allocations will be sealed in sequentially numbered opaque envelopes and
383 stored in the critical care area. When an eligible patient is enrolled, the next
384 sequential envelope will be opened to reveal the treatment assignment. Skipping a
385 study number is not allowed.

386

387 **4.1.2 Study Treatment and Blinding**

388

389 The study will be unblinded because it is not possible to blind physicians to this
390 study, and no sham intervention is possible.

391

392 **4.2 Assessments**

393

394 **4.2.1 Outcome Assessments**

395

396 Described in section 3

397

398 **4.2.2 Safety Assessments**

399

400 Any adverse events related to the use or non-use of the GEB should be observed
401 immediately in the ED during the intubation process. If either device fails to

402 intubate the patient, a second attempt will be performed. The second attempt can
403 proceed with any device or strategy that the intubating physician feels is best for the
404 patient. Direct trauma to the mouth, upper airway, and airway are possible in both
405 groups. Full assessment of the mouth, upper airway, and airway is not possible
406 without exposing the patient to further harm from repeated laryngoscopy and
407 bronchoscopy. Therefore, to assess any direct trauma, the intubating physician will
408 be asked if there was any direct trauma to the mouth, upper airway, or airway, and
409 if there was any excessive bleeding during or after intubation while in the ED.

410

411

412 **4.3 Study Duration**

413

414 A patient's participation in this trial will begin at enrollment, and end 1-minute after
415 successful intubation. No further data will be collected from the patient or
416 electronic medical record.

417

418 **5 STUDY POPULATION SELECTION**

419

420 **5.1 Study Population**

421

422 Adult patients undergoing orotracheal intubation in the ED with a Macintosh blade
423 (using either video or direct laryngoscopy) for any indication will be enrolled into
424 the study. To be eligible for enrollment, the patient must meet all of the inclusion
425 criteria and none of the exclusion criteria.

426

427 The subgroup of patients with any of the following difficult airway characteristics
428 will be the primary analysis population, though all enrolled patients will be included
429 in a secondary analysis. Difficult airway characteristics include: cervical immobility,
430 obesity, large tongue, short neck, small mandible, facial or neck trauma, airway
431 edema, blood in the airway, or vomit in the airway.

432

433

434 **5.2 Inclusion Criteria**

435

436 Patients must meet all of the following criteria to be eligible to participate in the
437 study:

438

- 439 1. The patient must be undergoing orotracheal intubation in the ED with
440 a Macintosh blade (using either video or direct laryngoscopy)
- 441 2. The patient must be presumed to be 18 years of age or older at the
442 time of enrollment.

443

444 **5.3 Exclusion Criteria**

445

446 Patients who meet any of the following criteria are not eligible to participate in this
447 study:

448

- 449 1. Known anatomic distortion of the upper airway or perilaryngeal
450 structures.
- 451 2. Prisoner or under arrest
- 452 3. Known or suspected to be pregnant, based on the opinion of the
453 treating physician.

454

455

456 **5.4 Subject Withdrawal Criteria**

457

458 As the study duration is very short, there will not be time for subject withdrawal.

459

6 STUDY CONSENT

This investigation will be conducted under 45 CFR 46.116 Waiver of Informed Consent, as both devices are standard of care.

45 CFR 46.116 (d) is copied below:

(d) An IRB may approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent set forth in this section, or waive the requirements to obtain informed consent provided the IRB finds and documents that:

(1) The research involves no more than minimal risk to the subjects;

(2) The waiver or alteration will not adversely affect the rights and welfare of the subjects;

(3) The research could not practicably be carried out without the waiver or alteration; and

(4) Whenever appropriate, the subjects will be provided with additional pertinent information after participation.

(e) The informed consent requirements in this policy are not intended to preempt any applicable federal, state, or local laws which require additional information to be disclosed in order for informed consent to be legally effective.

(f) Nothing in this policy is intended to limit the authority of a physician to provide emergency medical care, to the extent the physician is permitted to do so under applicable federal, state, or local law.

6.1 Research involves no more than minimal risk to the subjects

The use or non-use of the GEB both are the current standard of care in the Emergency Department. The decision whether to use a GEB depends on the intubating physician's preferences and biases. The resident physicians (who perform approximately 98% of the endotracheal intubations) receive extensive training in intubating with and without a GEB, and routinely perform endotracheal intubation with and without a GEB.

Though patients requiring intubation are critically ill by definition, and have significant risk of morbidity and mortality throughout the hospital stay, this risk is imparted by the underlying illness or injury, and should not be altered more than

502 minimally by the use or non-use of a GEB for intubation. Because both methods are
503 acceptable as standard of care for the first intubation attempt, there is currently no
504 reason to think that one has any higher risk than the other; that is, there is minimal
505 added risk to the patient beyond the risk caused by their severe illness or injury.

506
507
508

509 **6.2 The waiver or alteration will not adversely affect the** 510 **rights and welfare of the subjects**

511

512 There is no reason this waiver of consent could adversely affect the rights nor
513 welfare of the subjects. All subjects will receive the highest level of care provided by
514 the HCMC Emergency Physicians. All other care is at the discretion of the treating
515 physicians.

516

517 **6.3 The research could not practicably be carried out** 518 **without the waiver or alteration**

519

520 Patients who require emergent endotracheal intubation in the ED are critically ill by
521 definition. Many are obtunded or comatose; others are dyspneic and unable to talk;
522 still others have myriad severe illnesses that preclude an involved discussion
523 regarding the study along with its risks and benefits. For these reasons, it is not
524 practical to obtain informed consent for this investigation for the vast majority of
525 critically ill patients.

526

527 A patient who requires emergent endotracheal intubation has a pressing need for
528 medical intervention that cannot be delayed for any reason. Orotracheal intubation
529 must be completed on an emergent basis, and cannot wait for the consent of a
530 legally authorized representative (LAR), unless the LAR is at the bedside of the
531 patient.

532

533 Patients who are critically ill often become critically ill unexpectedly. There are a
534 multitude of acute illnesses that occur without warning: major trauma, head trauma,
535 stroke, spontaneous intracranial hemorrhage, sepsis, drug overdose, acute coronary
536 syndrome, and many others. There is no reasonable method to prospectively
537 identify individual patients likely to become eligible for participation in this clinical
538 trial.

539

540 If only critically ill patients who *were* able to provide informed consent were
541 included in this study, the results would not be generalizable to critically ill who
542 could not provide informed consent, as this is a more ill cohort.

543

544 Previous randomized trials examining emergency intubation have been completed
545 under a waiver of informed consent.^{33,34}

546

547

548 **6.3.1 Patient objection**

549

550 Because this trial involves no more than minimal risk to the patient, and because
551 endotracheal intubation must be completed emergently, the patient will not be
552 approached for consent. In the unlikely event the patient is able to have a reasoned
553 conversation prior to intubation, the patient will be asked if he/she would like to
554 decline being in a research study. If the patient declines, he/she will not be enrolled.

555

556 **6.3.2 LAR or Family member objection**

557

558 If a LAR or family member is at the bedside prior to endotracheal intubation, they
559 will be asked if they object to the patient being enrolled in an emergency airway
560 investigation. If they object, the patient will not be enrolled

561

562 **6.4 Notification after enrollment**

563

564 As the soonest feasible opportunity after study enrollment, the patient or the
565 patient's LAR will be notified of the study enrollment. Details of the investigation
566 will be provided on an information sheet with the contact information of the
567 investigators and research office.

568

569 Because the study will have been completed 1 minute after successful intubation, it
570 will not be possible to withdraw from the study.

571

572

573 **7 STUDY PROCEDURES**

574

575 Detailed descriptions of patient evaluations required for this protocol are described
576 in this section. These evaluations will be performed during the indicated times of
577 the study as detailed.

578

579 **7.1 Study Entrance Criteria**

580

581 At baseline, each patient will be reviewed for eligibility against the study entrance
582 criteria. Patients who do not meet the study entrance criteria will not be allowed to
583 participate in the study. Patient eligibility according to the study inclusion and
584 exclusion criteria will be confirmed at baseline.

585

586 **7.2 Enrollment**

587

588 If the patient is eligible for enrollment and neither the patient nor a LAR or family
589 member object to enrollment, the patient will be enrolled into the study. Upon
590 enrollment, the study allocation will be revealed and disclosed to the treating
591 physicians.

592

593 **7.3 Baseline and ED Data Collection**

594

595 Baseline vital signs will be collected immediately after randomization. If time
596 permits, the intubating physician will be asked to determine which, if any, difficult
597 airway characteristics the patient has. This data will be recorded on a structured
598 data collection form. Attempts at endotracheal intubation will be collected in real
599 time. Further baseline information, and information regarding difficult airway
600 characteristics (if not already gathered), will be obtained after the patient has left
601 the critical care area. All data gathered is listed in Appendix 1.

602

603

604 **7.4 Adverse Event Assessments**

605

606 Any adverse events (AE) related to the use or non-use of the GEB should be
607 observed immediately in the ED during the intubation process. If either device fails
608 to intubate the patient, a second attempt will be performed. The second attempt can
609 proceed with any device or strategy that the intubating physician feels is best for the
610 patient. Direct trauma to the mouth, upper airway, and airway are possible in both
611 groups. Full assessment of the mouth, upper airway, and airway is not possible
612 without exposing the patient to further harm from repeated laryngoscopy and
613 bronchoscopy. Therefore, to assess any direct trauma, the intubating physician will
614 be asked if there was any direct trauma to the mouth, upper airway, or airway, and
615 if there was any excessive bleeding during or after intubation while in the ED.

616

617 **7.4.1 Adverse Event Monitoring and Period of Observation**

618

619 AEs will be monitored continuously while the patient is in the ED, during which any
620 AE related to the study would be evident..

621

622

623 **7.4.2 Reporting Serious Adverse Events**

624

625 The local IRB will be notified of any related severe and unexpected, life-threatening,
626 or fatal SAE as soon as possible, generally within 24 hours depending on the day of
627 week. The data safety and monitoring board will also be notified as soon as possible.

628

629

630 **7.5 Safety-Related Stopping Rules**

631

632 An independent data safety and monitoring board (DSMB) will be established to
633 provide an ongoing, independent review and assessment of the safety data, and to
634 safeguard the interests and safety of the participating patients in the study.

635

636 On an ongoing basis, the DSMB will review SAEs that are judge to be at least possibly
637 related to the study. The DSMB will be notified immediately of the SAE and
638 requested to make an assessment within five working days. Based on the DSMB's
639 assessment of the event, as well as evaluation of the overall accumulating safety
640 data from the trial, the DSMB will make a recommendation as to whether the study
641 should be halted if there is a safety concern or should continue as planned.

642

643 See section 8.7.2 for possible stopping after the planned interim analysis.

644

645

646

647 **8 PLANNED STATISTICAL METHODS**

648

649 **8.1 General Considerations**

650

651 All statistical analyses will be performed with STATA Version 12.1 (StataCorp. 2011.
652 College Station, TX).

653 Unless otherwise specified, summary tabulations will be presented by treatment
654 group. For categorical variables, the number and percentage of patients within each
655 category (with a category for missing data as needed) of the parameter will be
656 presented. For continuous variables, the number of patients, mean, median,
657 standard deviation, minimum, and maximum values will be presented. Time-to-
658 event data will be summarized using Kaplan-Meier estimates of the 25th, 50th, and
659 75th percentiles with associated two-sided 95% CI, as well as percentage of
660 censored observations.

661 Formal statistical hypothesis testing will be performed on the primary and key
662 secondary outcomes, with all tests conducted at the 2-sided, 0.05 level of
663 significance.

664 **8.2 Sample size calculation**

665 Assuming a first pass success rate in the GEB group of 95%, to detect an absolute
666 difference of 9% (86% without use of GEB) with 80% power between groups, 374
667 patients (187 per group) with a difficult airway characteristic will need to be
668 enrolled. Approximately 1,500 patients are intubated annually in our Emergency
669 Department. Because of logistic considerations, we predict that only 1,000 patients
670 will be able to be enrolled, 30-40% of whom will have a difficult airway
671 characteristic. Therefore, we plan to enroll for 1 calendar year, or until we enroll
672 1,000 patients, whichever occurs first. If we have not enrolled 374 patients with a
673 difficult airway characteristic at that time, we will discuss with the IRB about
674 extending the timeframe of the investigation.

675 This sample size calculation was performed in STATA version 12.1 with the
676 following command: sampsi 0.95 0.86, p(0.8).

677

678 **8.3 Method of Assigning Study Patients to Treatment Groups**

679 See section 4.1.1.

680 **8.4 Population Description**

681

682 **8.4.1 Analysis Populations**

683 The intent-to-treat (ITT) population will be the primary outcome analysis
684 population. This group will include all patients who are endotracheally intubated
685 after randomization, excluding those intubated with a device other than a Macintosh
686 Blade, because this group could not possibly use a bougie or endotracheal tube.
687 Patients who have no intubation attempt performed will not be a part of the ITT
688 population and will be considered screening failures. This will sometimes occur
689 because emergent endotracheal intubation is planned, but the patient's condition
690 sometimes rapidly improves, obviating the need for intubation. Because this is a
691 patient group that is vastly different than patients who are intubated, and because
692 they received no airway procedure, they will not be included in the ITT analysis.

693 The primary outcome will be analyzed for the subset of patients in the ITT
694 population who have any difficult airway characteristic. This will be the main
695 outcome of the investigation. The data from all enrolled patients will also be
696 presented in the final analysis, as it is plausible that the GEB improves first pass
697 success significantly in even routine intubations.

698 **8.4.2 Treatment Compliance**

699 It is anticipated there will no patient compliance issues. The actual device used for
700 the first intubation attempt will be recorded, and the number of times this deviates
701 from protocol will be recorded. The IRB will be notified of all protocol deviations.

702 **8.5 Outcome Analysis**

703
704 The chi square test will be used to compare the primary outcome between the two
705 treatment groups, with the primary analysis including only those with any difficult
706 airway characteristic, and a secondary analysis of all enrolled patients.

707
708 Secondary outcomes with categorical and continuous variables will be analyzed as
709 the appropriate confidence interval of the difference between the two groups, again
710 stratified by the presence of any difficult airway characteristic.

711
712 Other data will be presented descriptively.

713
714

715 **8.6 Statistical/Analytic Issues**

716

717 **8.6.1 Handling of Missing Data**

718

719 For the primary outcome, if both the research assistant data collection form and the
720 treating physician post-intubation collection form are missing, the stabilization case

721 video will be reviewed to determine if first pass success without hypoxemia was
722 achieved. If the video is not available, the patient will be excluded from the analysis.

723

724 Secondary outcomes: if data for these outcomes is missing, the stabilization case
725 video will be reviewed to ascertain the true value(s). If the video is missing, the
726 patient will be excluded from analysis of the relevant outcomes.

727

728 **8.6.2 Interim Analysis and Data Monitoring**

729

730 An interim analysis will be performed after 500 patients are enrolled. The data will
731 be analyzed for the primary outcome only.

732 The trial will be stopped early only for futility. After the data from the first 500
733 patients is analyzed, a sensitivity analysis will be performed. An analysis will be
734 performed with a sample size of 1000 patients (equal allocation in both arms) with
735 the following assumptions:

- 736 • First pass success rate with non-use the GEB remains the same in the second
737 half of the trial
- 738 • First pass success rate with use of the GEB is 15% higher (absolute difference,
739 up to a success rate of 100%) than observed in the first half of the study
740

741 If no difference is found in first pass success with this analysis, then the trial will be
742 stopped early for futility.

743 As detailed in section 9.2, an independent DSMB will be established to provide an
744 ongoing, independent review and assessment of the safety data, and to safeguard
745 the interests and safety of the participating patients in the study. Any additional
746 analyses for DSMB review may be scheduled at the discretion of the DSMB.

747

748 **9 ADMINISTRATIVE CONSIDERATIONS**

749

750 **9.1 Institutional Review Board Approval**

751

752 The study will not be initiated until written IRB approval has been obtained for this
753 investigation.

754 **9.2 Data monitoring committee**

755

756 An independent DSMB will be established to provide an ongoing, independent
757 review and assessment of the safety data, and to safeguard the interests and safety
758 of the participating patients in the study. The DSMB will include Michelle Biros, MD.
759 ***

760 On an ongoing basis, the DSMB will review SAEs that are judged to be at least
761 possibly related to study drug. The DSMB may also be asked to review on an
762 ongoing basis other SAEs of concern. The DSMB will be notified immediately of the
763 SAE and requested to make an assessment within five working days. Based on the
764 DSMB's assessment of the event, as well as evaluation of the overall accumulating
765 safety data from the trial, the DSMB will make a recommendation as to whether the
766 study should be halted if there is a safety concern or should continue as planned.

767

768 **9.3 Protocol Violations/Deviations**

769

770 The investigator will conduct the study in compliance with the protocol. The
771 protocol will not be initiated until the IRB and the appropriate regulatory
772 authorities have given approval. Changes to the protocol will require written IRB
773 approval opinion prior to implementation, except when the modification is needed
774 to eliminate an immediate hazard(s) to patients. The IRB may provide expedited
775 review and approval for minor change(s) in ongoing studies that have the approval
776 of the IRB.

777 Any departures from the protocol will be fully documented as a protocol deviation.
778 Protocol deviations will be required to be submitted to the IRB.

779 **9.4 Premature Closure of the Study**

780

781 If the investigator, DSMB, or regulatory authorities discover conditions arising
782 during the study that indicate that the clinical investigation should be halted due to
783 an unacceptable patient risk, the study may be terminated.

784

10 LIST OF REFERENCES

- 785
786
787 1. Sakles JC, Chiu S, Mosier J, Walker C, Stolz U. The Importance of First Pass
788 Success When Performing Orotracheal Intubation in the Emergency Department.
789 Reardon RF, ed. *Academic Emergency Medicine*. 2013;20(1):71-78.
790 doi:10.1111/acem.12055.
- 791 2. Brown CA, Bair AE, Pallin DJ, Walls RM, NEAR III Investigators. Techniques,
792 success, and adverse events of emergency department adult intubations. *Annals of*
793 *Emergency Medicine*. 2015;65(4):363–370.e1.
794 doi:10.1016/j.annemergmed.2014.10.036.
- 795 3. Kidd JF, Dyson A, Latto IP. Successful difficult intubation. Use of the gum elastic
796 bougie. *Anaesthesia*. 1988;43(6):437-438.
- 797 4. Sellers WF, Yogendran S. Difficult tracheal intubation. *Anaesthesia*.
798 1987;42(11):1243.
- 799 5. Macintosh RR. *An Aid to Oral Intubation*. British Medical Journal; 1949.
- 800 6. Dogra S, Falconer R, Latto IP. Successful difficult intubation. Tracheal tube
801 placement over a gum-elastic bougie. *Anaesthesia*. 1990;45(9):774-776.
- 802 7. McCarroll SM, Lamont BJ, Buckland MR, Yates AP. The gum-elastic bougie: old
803 but still useful. *Anesthesiology*. 1988;68(4):643-644.
- 804 8. Nolan JP, Wilson ME. An evaluation of the gum elastic bougie. Intubation times
805 and incidence of sore throat. *Anaesthesia*. 1992;47(10):878-881.
- 806 9. Williamson JA, Webb RK, Szekely S, Gillies ER, Dreosti AV. The Australian
807 Incident Monitoring Study. Difficult intubation: an analysis of 2000 incident
808 reports. *Anaesth Intensive Care*. 1993;21(5):602-607.
- 809 10. Detave M, Shiniara M, Leborgne J-M. [Use of Eschmann's gum elastic bougie in
810 difficult orotracheal intubation, an audit over eight years of clinical practice]. *Ann*
811 *Fr Anesth Reanim*. 2008;27(2):154-157. doi:10.1016/j.annfar.2007.11.006.
- 812 11. Latto IP, Stacey M, Mecklenburgh J, Vaughan RS. Survey of the use of the gum
813 elastic bougie in clinical practice. *Anaesthesia*. 2002;57(4):379-384.
- 814 12. Walsh R, Cookman L, Luerssen E. Comparison of intubation performance by
815 emergency medicine residents using gum elastic bougie versus standard stylet in
816 simulated easy and difficult intubation scenarios. *Emergency Medicine Australasia*.
817 2014;26(5):446-449. doi:10.1111/1742-6723.12280.
- 818 13. Nolan JP, Wilson ME. Orotracheal intubation in patients with potential cervical
819 spine injuries. An indication for the gum elastic bougie. *Anaesthesia*.
820 1993;48(7):630-633.

- 821 14. Gataure PS, Vaughan RS, Latto IP. Simulated difficult intubation. Comparison of
822 the gum elastic bougie and the stylet. *Anaesthesia*. 1996;51(10):935-938.
- 823 15. Nocera A. A flexible solution for emergency intubation difficulties. *Ann Emerg*
824 *Med*. 1996;27(5):665-667.
- 825 16. Groves J, Edwards N, Hood G. Difficult intubation following thoracic trauma.
826 *Anaesthesia*. 1994;49(8):698-699.
- 827 17. Combes X, Le Roux B, Suen P, et al. Unanticipated difficult airway in
828 anesthetized patients: prospective validation of a management algorithm.
829 *Anesthesiology*. 2004;100(5):1146-1150.
- 830 18. Phelan MP, Moscati R, D'Aprix T, Miller G. Paramedic use of the endotracheal
831 tube introducer in a difficult airway model. *Prehosp Emerg Care*. 2003;7(2):244-
832 246.
- 833 19. Prekker ME, Kwok H, Shin J, Carlbom D, Grabinsky A, Rea TD. The process of
834 prehospital airway management: challenges and solutions during paramedic
835 endotracheal intubation. *Critical Care Medicine*. 2014;42(6):1372-1378.
836 doi:10.1097/CCM.0000000000000213.
- 837 20. Jabre P, Combes X, Leroux B, et al. Use of gum elastic bougie for prehospital
838 difficult intubation. *American Journal of Emergency Medicine*. 2005;23(4):552-
839 555.
- 840 21. Brazil V, Grobler C, Greenslade J, Burke J. Comparison of intubation performance
841 by junior emergency department doctors using gum elastic bougie versus stylet
842 reinforced endotracheal tube insertion techniques. *Emergency Medicine*
843 *Australasia*. 2012;24(2):194-200. doi:10.1111/j.1742-6723.2011.01506.x.
- 844 22. Tandon N, McCarthy M, Forehand B, Carlson JN. Comparison of intubation
845 modalities in a simulated cardiac arrest with uninterrupted chest compressions.
846 *Emergency Medicine Journal*. 2014;31(10):799-802. doi:10.1136/emered-2013-
847 202783.
- 848 23. Messa MJ, Kupas DF, Dunham DL. Comparison of bougie-assisted intubation
849 with traditional endotracheal intubation in a simulated difficult airway. *Prehosp*
850 *Emerg Care*. 2011;15(1):30-33. doi:10.3109/10903127.2010.519821.
- 851 24. Shah KH, Kwong BM, Hazan A, Newman DH, Wiener D. Success of the gum
852 elastic bougie as a rescue airway in the emergency department. *J Emerg Med*.
853 2011;40(1):1-6. doi:10.1016/j.jemermed.2008.04.045.
- 854 25. Shah KH, Kwong B, Hazan A, Batista R, Newman DH, Wiener D. Difficulties
855 with gum elastic bougie intubation in an academic emergency department. *J*
856 *Emerg Med*. 2011;41(4):429-434. doi:10.1016/j.jemermed.2010.05.005.

- 857 26. Gardner M, Janokwski S. Detachment of the tip of a gum-elastic bougie.
858 *Anaesthesia*. 2002;57(1):88-89.
- 859 27. Latto P. Fracture of the outer varnish layer of a gum elastic bougie. *Anaesthesia*.
860 1999;54(5):497-498.
- 861 28. Smith BL. Haemopneumothorax following bougie-assisted tracheal intubation.
862 *Anaesthesia*. 1994;49(1):91.
- 863 29. Kadry M, Popat M. Pharyngeal wall perforation--an unusual complication of blind
864 intubation with a gum elastic bougie. *Anaesthesia*. 1999;54(4):404-405.
- 865 30. Prabhu A, Pradhan P, Sanaka R, Bilolikar A. Bougie trauma--it is still possible.
866 *Anaesthesia*. 2003;58(8):811-813.
- 867 31. Staikou C, Mani AA, Fassoulaki AG. Airway injury caused by a Portex single-use
868 bougie. *J Clin Anesth*. 2009;21(8):616-617. doi:10.1016/j.jclinane.2009.03.006.
- 869 32. Arndt GA, Cambray AJ, Tomasson J. Intubation bougie dissection of tracheal
870 mucosa and intratracheal airway obstruction. *Anesthesia & Analgesia*.
871 2008;107(2):603-604. doi:10.1213/ane.0b013e318176fe36.
- 872 33. Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid
873 sequence intubation in acutely ill patients: a multicentre randomised controlled
874 trial. *Lancet*. 2009;374(9686):293-300. doi:10.1016/S0140-6736(09)60949-1.
- 875 34. Tekwani KL, Watts HF, Sweis RT, Rzechula KH, Kulstad EB. A comparison of
876 the effects of etomidate and midazolam on hospital length of stay in patients with
877 suspected sepsis: a prospective, randomized study. *Annals of Emergency Medicine*.
878 2010;56(5):481-489. doi:10.1016/j.annemergmed.2010.05.034.
- 879
- 880
- 881